CD22 and acute lymphoblastic leukemia: Indeed, a major challenge in developing immunotherapies for hematologic malignancies, for instance, acute lymphocytic leukemia (ALL), is that cancer cells can lose the CD19 antigen while retaining CD22 after CD19 shedding (32).